Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)
Conditions: Amyloidosis
Sponsor: Hospital Italiano de Buenos Aires

Version 6: Date 2025/04 
Amyloidosis - author POSADAS 
 
INSTITUTIONAL AMYLOIDOSIS 
REGISTRY OF THE ITALIAN 
HOSPITAL OF BUENOS AIRESCEPI 
Protocol No.: 1675 
Clinical Research Area in Internal Medicine 
Manual of Procedures for the Institutional 
Amyloidosis Registry 
 
Amyloidosis is a systemic disease resulting from the deposition of usually misfolded 
proteins in the form of amorphous fibrillar material in various tissues, potentially 
causing progressive dysfunction [1]. The prevalence of amyloidosis varies 
depending on the population and the type of amyloid. While the prevalence in the 
general population is unknown, estimates from the Mayo Clinic suggest it is 1 in 
90,666% in the US [2]. In England, it generated approximately 
0.0084% (1367/16232579) of the total hospital consultations between April 2008 
and April 2009[3]. 
The most frequent clinical manifestations are cardiac, renal, and hepatic 
involvement, but these vary widely depending on the type of amyloidosis, the 
affected organ, and the extent of the deposits [4]. Amyloid infiltration can produce 
signs and symptoms that may be very similar to other rheumatological pathologies 
[5]. This potentially polymorphic clinical presentation may suggest underdiagnosis 
due to low clinical suspicion. 

Records are organized systems for the systematic collection of data from a large 
number of patients in a fast and efficient manner, about a particular disease, at a 
given time [6, .]. 
The main difficulty with registries is ensuring the quality of their data. The main 
objectives of registries are [7]: 
1. Understand the risk and prognostic factors of the disease. 
2. Evaluate the diagnostic and therapeutic management by comparing it with 
current standards. 
3. To advance knowledge of diseases in order to optimize the assessment, 
treatment and follow-up of patients. 
4. Analyze the effectiveness of new therapies. 
5. Study the differences between different populations. 
6. Quickly estimate morbidity, mortality, and resource utilization associated 
with a pathological entity. 
7. Examine the course of a disease 
8. Formulate novel hypotheses for the subsequent performance of prospective 
studies. 
Currently, there are registries for patients diagnosed with transthyretin amyloidosis 
(TAHOS) [8], and a global transplant registry for patients with familial amyloid 
polyneuropathy [9]. There are also indirect registries such as those for kidney 
transplantation, heart transplantation, and others [10]. 
We found no data on the prevalence, incidence, progression, or prognosis of 
amyloidosis in our country. There are also no current amyloidosis registries. 
national or Latin American studies that could describe the behavior of this disease 
in our setting are essential. Because it is a chronic disease with amyloid infiltration 
and can produce signs and symptoms that are very similar to other rheumatological 
pathologies [5, 11], this potentially polymorphic clinical presentation may suggest 
underdiagnosis due to low clinical suspicion. Furthermore, there is no curative 
treatment, and some patients experience persistent symptoms despite appropriate 
therapy [12, 13]. Therefore, the creation of [a research group/research 
group/research group] is fundamental. 
A monitoring system that generates data on disease progression and prognosis. 
Data from these registries can be used to develop new treatment guidelines and 
recommendations, and to inform and educate physicians on the management of 
this disease. 
Because the Italian Hospital of Buenos Aires is a high-complexity referral center for 
this type of pathology and given that the hospital's prepaid health plan provides a 
unique opportunity for denominators to generate a population registry of its 

members, we propose to create an Institutional Amyloidosis Registry. 
Goals  
Primary objectives 
Creation of a system ofPopulation Registry of Amyloidosiswith prospective 
survey of epidemiological data, risk factors, diagnosis, prognosis, treatment, 
follow-up and survival. 
Secondary objectives 
1. Describe the occurrence ofAmyloidosisin the population of HIBA in the 
Central Hospital. 
2. Describe the characteristics of the clinical presentation, evolution, and 
predisposing factors ofAmyloidosis. 
3. Describe epidemiological data through registry participation Latin American 
Amyloidosis Association.  
Population and methods. 
Design  
Multicenter Cohort Study 
Population  
The study population will consist of adults over 17 years of age diagnosed with 
amyloidosis. 
Table 1. Participating Centers 
 
City  
Hospital  
Regarding 
Montevideo, Uruguay  
Hospital 
de 
Clínicas, 
Myeloma 
Unit, 
Department 
of 
Hematology 
Eloísa Riva 
GELAMM-registry 
Latin American 
Amyloidosis 
Association 
 
Eloisa Riva 
Capital Buenos 
Aires 
(coordination) 
Italian Hospital of 
Buenos Aires 
Adel
Aguirre-Lourdes 
Posadas (IP 

change 2019) 
Autonomous City of 
Buenos Aires 
Buenos Aires Cardiology 
Institute 
Juan Pablo 
Costabel 
Rosario, Santa Fe 
Private Hospital ofRosario,
Gamma Group 
Carlos 
umontDunayevich 
Pilar, Buenos Aires 
Province 
Hospital Austral  
Sergio Baratta 
Autonomous City of 
Buenos Aires 
Hospital de Clínicas 
Veronica Volberg 
Autonomous City of 
Buenos Aires 
British Hospital ofBuenos 
Aires 
Pablo Young 
Autonomous City of 
Buenos Aires 
British Hospital of 
Buenos Aires 
Luciana León 
Cejas 
Buenos Aires 
Nestor 
Kirchner 
High 
Complexity Hospital, El 
Cruce 
Gisela 
Streitenberger 
Santa Cruz, Bolivia 
Foianini Clinic 
Carolina maria 
petit cwirko 
Autonomous City of 
Buenos Aires 
Favaloro 
Alejandro  
Quiroga, Adrian 
Fernandez 
Autonomous City of 
Buenos Aires 
Anchorena 
Josefina Parody 
Montevideo, Uruguay  
Galeno Clinic 
Franco Leoni 
Autonomous City of 
Buenos Aires 
CHEMICAL 
Jorge Thierer 
 
 
 
Cordoba, Cordoba 
Private University 
Hospital of Córdoba 
María Laura 
Martínez 
 

 
Scope 
The scope consists of the sectors of each senior citizens' hospital 
17 years with amyloidosis from the participating centers. 
The scope of the registry is the Italian Hospital of Buenos Aires. The registry will be 
institutional in nature, without excluding any area within the hospital setting. 
including the outpatient area (outpatient clinics, emergency room, demand and 
hospitalization in all areas of the central hospital). 
In a second stage, other centers will be incorporated according to a preliminary 
feasibility assessment and a training program designed to train the different 
components. 
Eligible population 
All patients over 18 years of age and from any health provider who have 
amyloidosis or are suspected of having it will be included. 
Selection criteria 
Inclusion Criteria 
Patients over 18 years of age with: 
Confirmed amyloidosis 
Demonstration of amyloid deposition by Pathological Anatomy in abdominal fat, 
bone marrow, rectum or involved organ (e.g., kidney, liver, sural nerve) 
Clinical case compatible with Amyloidosis but not confirmed: 
Cardiac: The presence of 2 or more of these points: 
Right and/or left heart failure 
ECG: decreased QRS complex voltage 
Echocardiogram: increased wall thickness with hyperechoic ventricular walls and 
increased interatrial septum thickness. No other clear cause of increased ventricular 
thickness (hypertension, valvular heart disease). 
Cardiac MRI: increased diffuse subendocardial gadolinium uptake on late images. 
Renal:  
Renal involvement plus serum lambda free chains 
Evidence of clonal proliferation of plasma cells. This includes serum/urinary 
monoclonal protein, plasma cells in bone marrow, abnormal serum light chain ratio, 
without evidence of amyloid deposition composed of light chain fragments by 
immunofluorescence or immunohistochemistry, both lambda and kappa 
Blood relatives of patients with confirmed familial amyloidosis 

who present with a clinical picture of polyneuropathy without an alternative 
cause and a confirmed mutation of the amyloidogenic protein gene 
Exclusion criteria 
1. Refusal to participate in the study or the informed consent process by the 
patient or legal representative or refusal to consent to participate in the study 
in the case of minors. 
Designs 
1. Prospective registration, with capture of consecutive cases and annual 
follow-up. 
2. Cross-sectional descriptive studies for prevalence studies. 
3. Follow-up cohort of patients with Amyloidosis or suspected Amyloidosis. 
4. Retrospective cohort in the Latin American Amyloidosis Registry.5. 
Data quality assessment and record validation. 
Data capture and collection circuit 
The system for capturing evaluable patients will detect suspected or confirmed 
cases of amyloidosis in real time and issue an alert (see below). A list of potentially 
eligible patients, called the watch list, will be generated. The registry coordinator 
will manage this list sequentially, assigning assessments to participating 
physicians. 
Patients meeting inclusion criteria and none of exclusion criteria will be evaluated 
in a standardized manner and the corresponding forms for the evaluation of the 
registry will be completed. 
 Data logging 
The evaluation for patient inclusion and the collection of data from the standardized 
interview will be carried out by specially participating physicians and uploaded to a 
form for each included episode. 
It will be the physician's responsibility to complete all fields of the CRF. Monitors will 
check the completeness of each patient's record before 
Provide the data to the data entry clerk. Any missing or clearly erroneous data may 
be completed by reassessing or re-interviewing the patient, if possible. 

Follow-up  
A fixed schedule of annual telephone evaluations will be used. Surveillance lists will 
be used to detect readmissions, mortality, and new requests for re-evaluation due 
to a new episode of amyloidosis in the electronic medical record. 
Loaded with data 
Data entry will be performed by the data entry clerk. Laboratory results and 
supplementary test results will be obtained from secondary databases using the 
highest quality validated source available. Administrative and inpatient data will be 
cross-referenced with secondary databases for patient interactions and the 
institutional registry. 
Data quality and completeness 
Laboratory and administrative data will be obtained from high-quality secondary 
databases. The remaining data will be collected by monitors using forms designed 
for that purpose. 
The data entry system will check for incomplete fields, which will then be sent back 
to the doctor for completion. This will occur after the data has been uploaded to the 
registry database. 
Supervisors will subsequently check the data for consistency and the presence of 
obviously erroneous data. Any detected anomalous data will be sent back to the 
monitor for completion and re-entering into the database. If there is no reliable 
source for the data, it will be considered lost. 
 
Data management and workflow for incorporating data into the CEPI 7014 
rare disease registry and biobank 
Retrospective data is expected. In the case of a biobank, from 16 years onwards, 
the current version of the biobank (currently version 3, approved 5-2024, attached) 
will be used for future research. 
Patient recruitment will be done through a help desk request. 
Research information management and/or direct reporting by interdisciplinary 
attending physicians will be used. Data collection will be carried out through review 
of electronic health records (EHRs) and/or requests to secondary databases for 
information management. Retrospective data on biological samples will be 
requested from the corresponding service (pathology, laboratory). Administrative 

and inpatient data will be cross-referenced with the secondary databases of the 
institutional and inpatient registries. 
A standardized form designed specifically for this purpose will be used to collect 
the information. 
To ensure that the data is reliable and complete, the forms will be structured and 
the person responsible for collecting the data will be trained. 
For follow-up, a retrospective review of the electronic health record (EHR) and/or a 
request to the information management help desk are planned. If contact with the 
patient or family member is required, the Informed Consent form will be customized 
with details of the contact method, such as a fixed schedule of telephone 
evaluations and/or email and/or REDCap and/or internal EHR messaging, 
depending on the Rare Disease Program unit 7014, with notification to CEPI. 
Surveillance lists will be used to detect events such as hospitalizations, mortality, 
and new requests for evaluation for new episodes in the EHR. 
Data loading and storage  
The registration form will be submitted through REDCap using validation rules to 
minimize data entry errors. REDCap adheres to confidentiality and security 
protocols, with access restricted to researchers who log in with their username and 
password. It allows for the identification of data fields according to established 
standards. 
The data will be stored in REDCap, a repository recommended by the Research 
Department and the Health Informatics Department for research. The mechanism 
for sharing and transferring databases will be as follows: access via passwords, 
with passwords sent through a different method than the database itself.A working 
group is planned, comprised of advanced students from the IUHI ESIN Program, a 
scholarship recipient (the project will be submitted for permanent funding), and the 
leaders of each Amyloidosis and EPF unit. The research professors will be 
responsible for the base and its maintenance. The corresponding task delegations 
will be presented with the periodic reports. 
Data validation  
It is essential to ensure that the data is reliable, clean, and clear. Validation will be 
provided during the form design phase and subsequently for analysis. Data 
cleaning will be performed through frequency analysis, searching for and verifying 
implausible values, and identifying missing data. 
Data processing and analysis  
Once the database is complete, all identifying information about the participants 
must be removed. When using statistical software, some variables will need to be 
recoded for analysis. The final data are usually stored on the hospital network with 

restricted access. 
The de-identification process will be carried out in accordance with HIPAA 
regulations, using the REDCap form's identification tool to remove identifying data 
so that it is not downloaded for analysis. 
The possibility of using the data for other research projects derived from the 
registry is foreseen. These projects must be submitted to CEPI. 
for its corresponding evaluation and opinion in accordance with the legal framework 
that regulates the investigation in CABA or Province of Bs As. 
For de-identified retrospective data, including data from secondary databases and 
retrospective data from biological samples, the informed consent requirement 
established by the CIOMS guidelines is waived (see section on ethical 
considerations). For projects involving prospective data collection, data reuse, or 
the use of samples in a prospectively collected biobank, the Informed Consent 
process of the amyloidosis registry in effect since November 20, 2019, will be 
incorporated, as well as biobank version 3. 
Projects associated with the Research Protocol Ethics Committee will be presented 
in accordance with hospital standard No. 93/23Access to data from research 
studies conducted at the institution 
1 Data analysis  
Annual written reports and open oral presentations will be held at the central 
conference. At the hospital level, information will be disseminated on the intranet 
with the same frequency to ensure access within the HIBA (Hospital Interzonal de 
Albacete). 
The presentations will include data on the evolution and development of the 
registry structure, data descriptions, and assessments of data quality and registry 
processes. The main objectives of these reports will be to implement improvements 
in the structure and data quality, and to generate hypotheses to be tested on the 
registry data. 
Statistical analyses will be performed by a team of physicians trained for this 
purpose. Continuous variables will be expressed using summary measures and 
measures of central tendency, selected according to the distribution of each 
particular variable. Qualitative variables will be expressed as proportions. Statistical 
tests will be selected according to the hypotheses and the characteristics of the 
data, as appropriate. 
The following will be calculated using the data recorded upon registration: 
Annual incidence/prevalence of amyloidosis in the HIBA population, crude, 
specific by sex and age group (age groups will be established by decade of 

life). 
Case descriptions: 
- Demographics:age, sex, place of origin 
- Symptoms: Frequencies of each of the symptoms with which the cases 
present themselves 
- Diagnosis:frequency of each of the diagnostic methods used. 
- Therapeutic:Frequency of use of each of the initial therapies, 
frequency of associated complications, duration of treatments 
Multiple logistic regression. Known risk factors and those under investigation 
will be included. 
With the tracking data: 
Survival analysis of these patients within the Italian Hospital. (Cox 
regression) Known and potential prognostic factors will be considered. 
Budget  
The registry is based on the systematic collection of observational data; therefore, 
it does not alter in any way the costs associated with patient evaluation, diagnosis, 
hospitalization, or treatment. These expenses will continue to be covered by each 
patient's individual insurance plan. 
Registration fees cover administrative and staff expenses. Administrative expenses 
include stationery costs, including all registration forms for each case. Both costs 
are covered by the Internal Medicine Department of the Hospital Italiano de Buenos 
Aires. 
The staff of the Amyloidosis Registry includes the Physicians, the Coordinator, the 
Data Entry, and the Area Supervisors. 
The fees and schedules for the Monitor Coordinator, Data Entry, and Supervisors 
will be agreed upon later. 
Currently, it does not have direct funding. For BIOBANCO, the EPF samples were 
identified as strategic institutional samples. Amyloidosis samples will be 
incorporated through the institutional amyloidosis registry 1675 and the rare 
disease registry 7014. 
Ethical considerations, data confidentiality and security 
Participation in the registry will be voluntary in all cases and certified through the 
oral informed consent process. There are many examples in the literature of 
disease registries that use oral consent. When the patient is unable to express their 
consent, it will be requested from their legal representative or a suitable family 
member [13-16]. 
At all times, the protection of the patient's identity and data will be observed in 
accordance with current legal regulations, specifically the National Law on the 

Protection of Personal Data 25.326 (Habeas Data), and in accordance with 
international regulations on disease registration and the protection of personal and 
private data, as established by the 18th World Medical Assembly in Helsinki (1964), 
where applicable. The right to opt out of registration will be respected at all times, 
and this will not imply any type of discrimination, differential treatment, or 
mistreatment. 
All documents or forms containing patient data from the registry are confidential 
and will be kept under lock and key with access restricted to authorized personnel 
of the institutional Amyloidosis registry. 
The head of the department and the hospital director are aware of the protocol 
In the case of other centers in the country, the principal investigator at each center 
will be responsible for presenting the proposal to their committee and requesting 
approval. The amendment for approval of the Protocol and additional centers will 
be submitted to CEPI, and the principal investigator at each center will be 
responsible for submitting the regulatory material requested by CEPI in order for it 
to be accepted. 
 
The HIBA Committee has no jurisdiction over centers in other countries, and the 
protocol must go through the regulatory procedures corresponding to that center 
and country. 
6. Ethical considerations for incorporating data into the register of 
rare 
diseases CEPI 7014 and biobank 
This research will be conducted in compliance with ethical principles in accordance 
with the regulatory standards for human health research at the national and 
international levels, in accordance with the regulatory standards for human health 
research at the national level (Resolution of the Ministry of Health of the Nation 
1480/2011 and Law 3301/09 of CABA), the Declaration of Helsinki of the World 

Medical Association and all its amendments, and respecting the ICH E6 Standards 
of Good Clinical Practice. 
All data from the study will be treated with maximum confidentiality, with restricted 
access only for personnel authorized for the purposes of the study in accordance 
with current legal regulations National Law on the Protection of Personal Data 
25.326/00 (Habeas data Law) and Law 26.529/09. 
Retrospective data - waiver of consent 
Given that, as stated in Chapter 10 of the International Ethical Guidelines for 
Health-Related Research Involving Human Subjects CIOMS/2017, this research: 
1-would not be feasible or viable to carry out without such a waiver or modification, 
given that it will involve a retrospective review of medical records or anonymized 
retrospective biological samples, and informed consent is not feasible to obtain, 
and within the framework of Law 26.689 on rare diseases, which establishes the 
creation of a national network and promotes the creation of a National Registry of 
people with a rare disease; 2-it has significant social value given that there is 
limited information on the clinical-epidemiological and anatomopathological 
characteristics of this population, given that amyloidosis is a rare disease; and 3-it 
entails only minimal risks for the participants, given that the data will be presented 
in a grouped and de-identified form; we request a waiver of the requirement to 
obtain informed consent. 
The plan is to collect retrospective data for the amyloidosis registry, the Rare 
Diseases Registry (7014), and the National Ministry of Health's Rare Diseases 
Registry via SISA, which contains general information about the individual, the 
diagnosis, data from the healthcare facility, and the treating professional. This 
health data is combined with other data also managed through SISA.Citizen's 
Record, which centralizes the various records associated with the same person 
Version 6: Date 2025/04 
14  
Amyloidosis - author POSADAS 
in a single and individual repository, because the law on rare diseases requires 
mandatory reporting. 
Prospective data 
In the case of projects that include prospective data collection, the Informed 
Consent process of the current amyloidosis registry (20-11-2019) will be 
incorporated. 
Data for the biobank 
The comprehensive consent form for BIOBANCO version 3 explicitly outlines the 
collection of biological samples to promote science as a common good, respecting 
patients' rights and the rights of citizens. The ethical and legal regulations 

considered in this informed consent form are: National Law 25.326 on data 
protection, National Law 26529 on patients' rights, Resolution 1480 - Guide for 
Health Research of the Ministry of Health of Argentina (2011), the UNESCO 
Declaration on the Protection of Genetic Data and Declaration on Bioethics and 
Human Rights, the World Medical Association's Declaration of Helsinki (2008 
version), and the CIOMS Guidelines (2009). For biobanking, the current version of 
the biobank (currently version 3, approved 5-2024) will be used for individuals aged 
16 and over. 
 
1. Gorevic, P.D., An overview of amyloidosis, in UpToDate, P.H. Schur and P.L. Romain, Editors. 2010, UpToDate: 
Waltham, MA.  
2. Prevalence and Incidence of Amyloidosis. Volume,  
3. Primary diagnosis: 3 character, 2008-09. www.hesonline.nhs.uk. 2009, UK: Hospital Episode Statistics HESonline - 
The Health and Social Care Information Centre.  
4. Simmons, Z. and C.S. Specht, The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis. 11(3): 
p. 145-57.  
5. Prokaeva, T., et al., Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular 
features, and survival. Arthritis Rheum, 2007. 56(11): p. 3858-68.  
6. Dyke, C.K. and R.M. Calif, National and regional registries: what good are they? Eur Heart J, 2000. 21(17): p. 
1401-3.  
7. Alpert, J.S., Are data from clinical registries of any value? Eur Heart J, 2000. 21(17): p. 1399-401. 
8. THAOS: TTR Amyloidosis Patient Registry 2010 [cited 2010.  
9. Herlenius, G., et al., Ten years of international experience with liver transplantation for familial amyloidotic 
polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation, 
2004. 77(1): p. 64-71.  
10. Roig, E., et al., Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry 
for heart transplantation. Am J Transplant, 2009. 9(6): p. 1414-9.  
11. Fujishima, M., et al., Amyloid arthropathy resembling seronegative rheumatoid arthritis in a patient with 
IgD-kappa multiple myeloma. Intern Med, 2003. 42(1): p. 121-4.  
12. Chin, K.M. and L.J. Rubin, Pulmonary arterial hypertension. J Am Coll Cardiol, 2008. 51(16): p. 1527-38.  
13. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. 
Heart, 2008. 94 Suppl 1: p. i1-41.  
14. Lizzi, A., G. Almada, and L. Clara, Practical Measures for the Control of Hospital Infections. 2002, Capital Federal 
Buenos Aires. Argentina: Infection Control Committee of the Italian Hospital of Buenos Aires. Preventio Foundation. 
15. Hulley, S.B. and R.S. Cummings, Designing Clinical Research. An epidemiologic aproach. 1988, Baltimore, USA: 
Williams & Wilkins.  
16. Bennett, S., et al., Data Management for Suveys and Trials. 1996, Llanidloes, Powys: Brixton Books. 17. 
Olson, J.E., Data Quality. The accuracy dimension. 2003, San Francisco, USA Morgan Kaufmann Publishers.  
18. Malone, T.W., K. Crowston, and G.A. Herman, Organizing Business Knowledge: The MIT Process Handbook. 
2003, Massachusetts, United States of America: The MIT Press.  
19. Amin, S.G., Control charts 101: a guide to health care applications. Qual Manag Health Care, 2001. 9(3): p. 1-27.  
20. Evans, J.R. and W.M. Lindsay, Quality Management and Control 1995, Mexico City, Mexico: Grupo Editorial 
Iberoamérica. 
21. Fuentes, N., et al. Hyponatremia associated with thiazide consumption in the patient population of a health plan. 
in XVII NATIONAL CONGRESS OF MEDICINE. 2009. Autonomous City of Buenos Aires. 
22. Millán Ramos, C., et al. Quality Indicators of the Institutional Registry of Thromboembolic Disease (RIET). in XVI 
National Congress of Medicine - SAM 2007 2007. Autonomous City of Buenos Aires, Argentina. 
23. Alcalde San Miguel, P., Quality. 2007, Madrid, Spain: Thomson Paraninfo. 

24. Mukerjee, D., et al., Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: 
application of a registry approach. Ann Rheum Dis, 2003. 62(11): p. 1088-93.  
25. National Law 25 326: Personal Data Protection Law. October 4, 2000, Sanctioned by the Senate and Chamber of 
Deputies of the Argentine Nation meeting in Congress. 
26. Ruiz Morales, A. and L.E. Morillo Zárate, Clinical Epidemiology: Applied Clinical Research. 2004, Bogotá DC, 
Colombia: Editorial Médica Panamericana. 
27. ICMJE. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for 
Biomedical Publication. 2006 February 2006 [cited June 24th, 2006]; http://www.icmje.org/#author]. 
Version 6: Date 2025/04 
16  
Amyloidosis - author POSADAS 
28. Rubin, L.J., Primary pulmonary hypertension. N Engl J Med, 1997. 336(2): p. 111-7.  
29. NEJM. AUTHOR CENTER 2006 [cited June 24th, 2006]; http://authors.nejm.org/index.asp].  
30. Gu, Q., et al., Antihypertensive medication use among US adults with hypertension. Circulation, 2006. 113(2): p. 
213-21.  
31. Collins, F.S., Shattuck lecture--medical and societal consequences of the Human Genome Project. N Engl J Med, 
1999. 341(1): p. 28-37.  
32. Annas, G.J., Rules for research on human genetic variation--lessons from Iceland. N Engl J Med, 2000. 342(24): 
p. 1830-3.  
33. Elias, S. and G.J. Annas, Generic consent for genetic screening. N Engl J Med, 1994. 330(22): p. 1611-3.  
34. Snider, G.L., Diagnosis of chronic obstructive pulmonary disease, in UpToDate version 13.2 B.D. Rose, Editor. 
2005: Wellesley, MA.  
35. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2008. 31 Suppl 1 p. S55-60.  
36. Sabate, J.M., et al., High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a 
contributor to severe hepatic steatosis. Obes Surg, 2008. 18(4): p. 371-7.  
37. Goldberg, E. and S. Chopra, Diagnostic approach to the patient with cirrhosis, in UpToDate version 13.2 B.D. 
Rose, Editor. 2005: Wellesley, MA.  
38. Garcia-Tsao, G., et al., Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology, 
1985. 5(3): p. 419-24.  
39. Johansson, P.L., S. Safai-Kutti, and J. Kutti, An elevated venous haemoglobin concentration cannot be used as a 
surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent 
polycythaemia. Br J Haematol, 2005. 129(5): p. 701-5.  
40. Congenital heart defects. 13/08/2009 NCBI.  
41. Lung Disease, Interstitial. 2009, NCBI.  
42. Brennan, P., et al., Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The 
UK Scleroderma Study Group. Br J Rheumatol, 1993. 32(5): p. 357-61.  
43. Jarvik, J.G., et al., Surgery versus non-surgical therapy for carpal tunnel syndrome: a randomised parallel-group 
trial. Lancet, 2009. 374(9695): p. 1074-81.  
44. Cossio, P., et al., Internal Medicine. 6th edition ed. 1997, Buenos Aires, Argentina: CTM. 
45. Barbera, J.A., et al., [Standards of care in pulmonary hypertension. Consensus Statement of the Spanish Society 
of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC)]. Arch Bronconeumol, 
2008. 44(2): p. 87-99.